Evidence map›Paper›PMID 39804848›Full record

Observational studyPloS one2025

Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States.

Jason R Gantenberg, Kathryn D Thompson, Robertus van Aalst, David M Smith, Megan Richards, Christopher B Nelson, William V La Via, Sandra S Chaves, Angela M Bengtson, David A Savitz and 1 more

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jason R GantenbergDepartment of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI, United States of America.ORCID 0000-0002-8144-4273
Kathryn D ThompsonDepartment of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI, United States of America.ORCID 0000-0002-7450-3837
Robertus van AalstDepartment of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI, United States of America.ORCID 0000-0003-3025-7811
David M SmithMerative, Cambridge, Massachusetts, United States of America.
Megan RichardsMerative, Cambridge, Massachusetts, United States of America.
Christopher B NelsonVaccines Medical Affairs, Sanofi, Swiftwater, Pennsylvania, United States of America.
William V La ViaVaccines Medical Affairs, Sanofi, Swiftwater, Pennsylvania, United States of America.ORCID 0000-0002-3819-5670
Sandra S ChavesNew Products and Innovation, Sanofi, Lyon, France.
Angela M BengtsonDepartment of Epidemiology, Emory University, Atlanta, GA, United States of America.
David A SavitzDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, United States of America.
Andrew R ZulloDepartment of Health Services, Policy and Practice, Brown University School of Public Health, Providence, RI, United States of America.ORCID 0000-0003-1673-4570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRespiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants. Characterizing service utilization during infant RSV hospitalizations may provide important information for prioritizing resources and interventions.

objectiveThe objective of this study was to describe the procedures and services received by infants hospitalized during their first RSV episode in their first RSV season, in addition to what proportion of infants died during this hospitalization.

methodsIn this retrospective observational study, we analyzed three different administrative claims datasets to examine healthcare service utilization during RSV hospitalizations among infants. The study population included infants born between July 2016 and February 2020 who experienced an RSV episode during their first RSV season and had an associated inpatient hospitalization. We stratified infants into three comorbidity groups: healthy term, palivizumab-eligible, and other comorbidities. Outcomes included extracorporeal membrane oxygenation, supplemental oxygen use (in-hospital and post-discharge), mechanical ventilation (invasive and non-invasive), chest imaging, infant mortality, length of inpatient stay, intensive care unit (ICU) admission, and number of days in the ICU.

resultsChest imaging was the most frequently administered procedure during RSV-associated hospitalizations, with approximately 34-38% of infants receiving it. Around one-quarter of infants were admitted to the ICU during their first RSV hospitalization. Median lengths of stay in the hospital were 3-4 days, extending to 4-6 days in the presence of ICU admission. Palivizumab-eligible infants had higher utilization of healthcare services and spent more time in the hospital or ICU compared to healthy infants or those with other comorbidities.

conclusionsThis study provides insights into the utilization of healthcare services during RSV hospitalizations among infants. Understanding service utilization patterns can aid in improved management and resource allocation for infants in the United States, ultimately contributing to better outcomes and reduced healthcare costs overall. However, likely under-ascertainment of ventilation and oxygen-related services in insurance claims remains an impediment to studying these outcomes.

Indexed as

HospitalizationPatient Acceptance of Health CareRespiratory Syncytial Virus InfectionsAntiviral AgentsFemaleHumansInfantInfant, NewbornInpatientsLength of StayMalePalivizumabRespiration, ArtificialRetrospective StudiesUnited StatesAntiviral AgentsPalivizumab

Identifiers

PMID39804848
PMCPMC11730397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.